Virinchi Limited has completed the allotment of 86 lakh convertible equity warrants to Vivo Bio Tech Limited through a preferential issue, following committee approval and regulatory clearances. The Stakeholders Relationship Committee approved the allotment on January 8, 2026, marking the completion of a significant corporate transaction between the two entities.

Warrant Allotment Details

The allotment encompasses comprehensive financial and structural parameters that define the investment arrangement:

Each convertible equity warrant carries the right to convert into one fully paid-up equity share of Virinchi Limited. The conversion requires payment of the remaining 75% of the issue price, amounting to ₹21.00 per warrant, within 18 months from the allotment date as per SEBI regulations.

Regulatory Framework and Approvals

The warrant allotment received comprehensive regulatory clearances through a structured approval process:

• Shareholder Approval: Virinchi Limited's shareholders approved the preferential issue at an Extra-Ordinary General Meeting held on November 15, 2025
• BSE Approval: In-principle approval granted via letter LOD/PREF/KS/FIP/1456/2025-26 dated December 31, 2025
• NSE Approval: In-principle approval provided through letter NSE/LIST/51564 dated December 31, 2025
• Committee Approval: Stakeholders Relationship Committee approved the allotment on January 8, 2026

Shareholding Impact Analysis

The warrant allotment will significantly impact the shareholding pattern upon conversion, strengthening the promoter group's position:

Vivo Bio Tech Limited, categorized as a promoter group entity, will see its stake increase by 4.83 percentage points upon full conversion of the warrants. The transaction follows SEBI (ICDR) Regulations, 2018, ensuring compliance with preferential issue norms.

Transaction Structure and Terms

The preferential allotment structure provides flexibility for both parties while ensuring regulatory compliance. Vivo Bio Tech Limited has paid the mandatory 25% upfront amount totaling ₹6.02 crores. The warrants can be exercised in one or more tranches within the 18-month conversion window. If warrants remain unexercised beyond this period, they will lapse and the paid amount will be forfeited by the company, providing certainty to the transaction timeline.

Vivo Bio Tech Limited has successfully completed the allotment of 90,000 equity shares through the conversion of warrants issued on a preferential basis. The pharmaceutical company announced this development in its regulatory filing dated January 06, 2026.

Share Allotment Details

The company allotted 90,000 equity shares of ₹10 each at an issue price of ₹45 per share, which includes a premium of ₹35 on each equity share. The allotment was made upon receipt of application money totaling ₹30,37,500, representing 75% of the total issue price.

Allottee Information

The entire allotment of 90,000 equity shares was made to Kompella Lopa Mudra, who belongs to the promoter group category. This preferential allotment strengthens the promoter group's stake in the company.

Impact on Share Capital

Following this allotment, Vivo Bio Tech Limited's issued and subscribed share capital has increased significantly. The company's total share capital now stands at ₹22,19,06,280, divided into 2,21,90,628 equity shares of ₹10 each.

This warrant conversion represents a strategic capital raising exercise by the company, providing additional funds while maintaining promoter group participation. The transaction was completed in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring proper regulatory disclosure to stakeholders.